QRG Capital Management Inc. Acquires 5,863 Shares of Edwards Lifesciences Corporation $EW

QRG Capital Management Inc. boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,327 shares of the medical research company’s stock after buying an additional 5,863 shares during the quarter. QRG Capital Management Inc.’s holdings in Edwards Lifesciences were worth $4,831,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of EW. Mirae Asset Global Investments Co. Ltd. grew its position in Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after buying an additional 648,870 shares during the period. Central Pacific Bank Trust Division acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $775,000. Sivik Global Healthcare LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $2,984,000. Finally, Stance Capital LLC grew its holdings in shares of Edwards Lifesciences by 373.1% during the third quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock valued at $3,577,000 after buying an additional 36,272 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. TD Cowen reaffirmed a “buy” rating and set a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $96.39.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 57,958 shares of company stock worth $4,839,284. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Trading Down 0.1%

Shares of Edwards Lifesciences stock opened at $94.31 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a fifty day moving average price of $85.61 and a 200 day moving average price of $83.57. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $94.47. The stock has a market cap of $54.31 billion, a PE ratio of 50.17, a price-to-earnings-growth ratio of 2.37 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm posted $0.64 earnings per share. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.